High Risk Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer Patients
Conditions
Keywords
prostate cancer, Non-metastatic prostate cancer, intermediate prostate cancer, high risk prostate cancer, very high risk prostate cancer, Memorial Sloan Kettering Cancer Center, 26-288
Brief summary
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
Interventions
RADIATIONStandard of Care HDR Brachytherapy
HDR Brachytherapy
RADIATIONSBRT
SBRT alone
Sponsors
Memorial Sloan Kettering Cancer Center
Palette Life Sciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Non-metastatic prostate cancer. * Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed) * Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in International Prostate Symptom Score / IPSS at 3 months | 3 months | Change in International Prostate Symptom Score / IPSS to measure if SBRT alone results in less acute patient reported urinary symptoms measured by IPSS at 3 months than HDR brachytherapy boost combined with SBRT |
Countries
United States
Contacts
CONTACTDaniel Gorovets, MD
CONTACTHimanshu Nagar, MD
PRINCIPAL_INVESTIGATORDaniel Gorovets, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed